-
Mashup Score: 6Acalabrutinib with lenalidomide and rituximab for R/R aggressive B-cell non-Hodgkin lymphoma - 23 hour(s) ago
Here, we summarize results from a phase II trial assessing the safety and efficacy of acalabrutinib in combination with lenalidomide and rituximab in patients with R/R B-cell NHL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Lisocabtagene maraleucel receives accelerated U.S. FDA approval for adult patients with R/R FL - 1 day(s) ago
Following positive response data from the phase II TRANSCEND FL study, lisocabtagene maraleucel receives accelerated U.S. FDA approval for the treatment of adult patients with R/R follicular lymphoma.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA grants accelerated approval to lisocabtagene maraleucel for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on response data from the phase II TRANSCEND FL trial 👉 https://t.co/gwTk9Vhn83 #lymphoma #MedNews https://t.co/jSV5KdnzMl
-
-
Mashup Score: 12
Here, we summarize results from the phase II CheckMate 436 trial investigating nivolumab plus brentuximab vedotin in patients with R/R PTCL and CTCL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Machine learning-based survival prediction models for advanced-stage Hodgkin lymphoma - 3 day(s) ago
Here, we summarize the development and validation of a machine learning-based, survival prediction model for patients with advanced-stage Hodgkin lymphoma published by Jørgensen et al. in JCO Clinical Cancer Informatics.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9
Here, we summarize results from an analysis comparing real-world outcomes of axicabtagene ciloleucel vs chemoimmunotherapy in patients with R/R LBCL with ≥2 previous lines of therapy.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9Nivolumab with CAR T-cell therapy in progressive DLBCL: final analysis of a phase II study - 10 day(s) ago
Here we summarize results from a phase II trial investigating the addition of nivolumab to CAR T-cell therapy in patients with progressive DLBCL, presented by Amit at EBMT 2024.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Here, we summarize an analysis of CD19-targeting CAR T-cell therapy in patients with PCNSL or SCNSL, presented by Ossami Saidy during the 50th Annual Meeting of the EBMT.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Camrelizumab plus GEMOX as salvage therapy for R/R cHL: Results from a phase II trial - 18 day(s) ago
Here, we summarize results from a phase II trial assessing the safety and efficacy of camrelizumab in combination with GEMOX followed by auto-HSCT in patients with R/R cHL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Lisocabtagene maraleucel as a second-line treatment for R/R LBCL: PROs from the PILOT study - 25 day(s) ago
Here, we summarize a health-related quality of life and patient-reported outcomes analysis from the phase II PILOT trial, published by Gordon et al. in Haematologica.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Correlation between MRD at the end of induction and EFS in pediatric T-cell lymphoblastic lymphoma - 1 month(s) ago
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free survival in pediatric patients with T-cell lymphoblastic lymphoma published by Hayashi et al.1 in Blood.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
Is acalabrutinib in combination with lenalidomide and rituximab well tolerated and effective in patients with R/R aggressive B-cell non-Hodgkin lymphoma? Read our summary of results from a phase II trial: https://t.co/aWLE4gR3ep. #lymphoma #lymsm #MedicalEducation https://t.co/pqF1uTM1R7